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Abstract
RNA interference (RNAi) is a powerful approach for silencing genes associated with a variety of
pathologic conditions; however, in vivo RNAi delivery has remained a major challenge due to lack
of safe, efficient, and sustained systemic delivery. Here, we report on a novel approach to
overcome these limitations using a multistage vector composed of mesoporous silicon particles
(stage 1 microparticles, S1MP) loaded with neutral nanoliposomes (dioleoyl phosphatidylcholine,
DOPC) containing small interfering RNA (siRNA) targeted against the EphA2 oncoprotein, which
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is overexpressed in most cancers, including ovarian. Our delivery methods resulted in sustained
EphA2 gene silencing for at least 3 weeks in two independent orthotopic mouse models of ovarian
cancer following a single i.v. administration of S1MP loaded with EphA2-siRNA-DOPC.
Furthermore, a single administration of S1MP loaded with-EphA2-siRNA-DOPC substantially
reduced tumor burden, angiogenesis, and cell proliferation compared with a noncoding control
siRNA alone (SKOV3ip1, 54%; HeyA8, 57%), with no significant changes in serum chemistries
or in proinflammatory cytokines. In summary, we have provided the first in vivo therapeutic
validation of a novel, multistage siRNA delivery system for sustained gene silencing with broad
applicability to pathologies beyond ovarian neoplasms.
Introduction
RNA interference (RNAi) therapy is emerging as a treatment modality of exceptional
promise, in view of its versatile application to the silencing of any gene with a known
sequence and especially those that are not drugable by existing approaches such as small-
molecule inhibitors. However, in vivo systemic administration of RNAi has remained a
major challenge due to its short half-life (1), lack of ability to penetrate the plasma
membrane (2), and potential toxicity (3, 4). Nanoparticle-based delivery systems have been
proposed to address these concerns. The validity of RNAi therapeutics has been shown in
animal models (3, 5–7) and more recently in human clinical trials (8, 9). For all of the
potential small interfering RNA (siRNA) delivery advantages they engender, nanoparticles
also have some limitations including their potential for rapid clearance (10), instability in
serum (11), and systemic toxicity, especially to the liver (3). Moreover, most of the current
RNAi delivery approaches require frequent injections (12, 13), which can be a substantial
impediment to patient treatment due to impaired enrollment on clinical trials and decreased
patient compliance (14). Thus, development of safe, easy to administer, and efficient
delivery systems that achieve sustained target gene silencing is of substantial clinical
importance.
Previously, we have shown that siRNA incorporated in neutral nanoliposomes (30–40 nm in
diameter) composed of dioleoyl phosphatidylcholine (DOPC) led to therapeutic gene
modulation in several orthotopic cancer models with no overt toxicities (12, 13). Although
our lipid-based siRNA delivery platform holds substantial promise for clinical translation, as
is the case for other nanocarriers, our method currently requires twice weekly injections to
achieve continuous gene silencing. We sought to develop a biocompatible approach that
would allow for the sustained delivery of siRNA resulting in continuous gene silencing,
therapeutic efficacy at nontoxic doses, and ease of administration. To attain these goals, we
have developed a multistage delivery approach (Fig. 1A) composed of two biodegradable
and biocompatible carriers: the first-stage carriers are mesoporous microscale biodegradable
silicon particles (stage 1 micro-particles: S1MP; ref. 15), allowing for the loading and
release of second-stage nanocarriers (DOPC nanoliposomal siRNA: siRNA-DOPC) in a
sustained manner. Here, we provide the first evidence that a single administration of
multistage siRNA-DOPC delivery resulted in sustained in vivo gene silencing for 3 weeks,
significant antitumor effect in two orthotopic mouse models of human ovarian cancer with
no observable concurrent toxicity.
Materials and Methods
Fabrication of porous silicon particles
Porous silicon particles were fabricated by electrochemical etching of silicon wafers as
previously described (15). The physical dimension and pore size of S1MP were verified by
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high-resolution scanning electron microscope. The porosity was verified by nitrogen
absorption analysis as previously described (15).
Surface chemistry of S1MP
Surface of the S1MP was hydroxylated in oxygen plasma (O2100sccm 50W). The positively
charged amine groups were introduced on the surface by silanization with 9% v/v 3-
aminopropyltriethoxysilane in isopropanol as previously described (15). The surface charge
was measured by Zeta Pals (Brookhaven Instruments).
Liposomal siRNA formulation
The siRNA liposomes were prepared as previously described (13) by mixing 1,2 dioleoylsn-
glycero-3-phosphocholine with siRNA (20:1, mol/mol) in the presence of excess t-butanol.
Control siRNAs (5′-AATTCTCCGAACGTGTCACGT-3′) and Alexa 555–tagged control
siRNA were purchased from Qiagen and siRNAs against EphA2 (5′-
AATGACATGCCGATCTACATG-3′) were purchased from Sigma (16). Dry film of DOPC
liposomes were reconstituted by adding water followed by briefly sonication.
Assembly of multistage vector
Amino functionalized S1MP (1 × 107 particles, 5 µg silicon) were mixed with t-butanol, and
dried and mixed with DOPC nanoliposomes containing fluorescently labeled siRNA. The
mixture was briefly sonicated and then spun down to remove any unincorporated free
DOPC-siRNA. Fluorescence intensity of the supernatants as well as the precipitants were
measured at Ex 555/Em 592 to assess loading efficacy.
Cell lines and culture
The human epithelial ovarian cancer cell lines such as HeyA8-Lc and Skov3ip1-Lc were
used for these studies. Cells were maintained in RPMI 1640 supplemented with 15% fetal
bovine serum and 0.1% gentamicin sulfate as described as previously (13). All experiments
were performed with 70% to 80% confluent cultures.
Orthotopic in vivo model of ovarian cancer and tissue processing
Female athymic nude mice (NCr-nu; 4- to 5-weekold) were purchased from Taconic Farms
and maintained as previously described (13). Institutional Animal Care and Use Committee
approval was obtained before all animal studies. All mouse studies were approved by the
M.D. Anderson Cancer Center Institutional Animal Care and Use Committee. Orthotopic
nude mouse models of ovarian carcinoma (17) were used for this study as previously
described.
Western blot analysis
Western blot was performed as previously described (13). Primary antibody against EphA2
was detected with horseradish peroxidase–conjugated IgG (Amersham) and developed using
an enhanced chemiluminescence detection kit (Pierce). Membranes were tested for β-actin
to confirm equal loading.
Immunohistochemistry
Ki67 and EphA2 staining were performed using formalin-fixed, paraffin-embedded tumor
sections (8-µm thickness) as previously described (8). For the evaluation of cell
proliferation, the proliferative indices were determined by counting the number of Ki67-
positive cells out of total number of cells in five randomly selected high-power fields
exclusive of necrotic areas at ×100 magnification. The data were expressed as percentage of
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Ki67-positive cells. For the measurement of microvessel density, the proliferative indices
were determined by counting the number of CD31-positive vessels in five randomly selected
high-power fields exclusive of necrotic areas at ×100 magnification. All staining was
quantified by two investigators in a blinded fashion.
Inductively coupled plasma atomic emission spectroscopy analysis for silicon content
The organs were lysed, spun down, and then analyzed for silicon content using inductively
coupled plasma atomic emission spectroscopy. We detected silicon at 250.69, 251.43,
251.61, and 288.158 nm and Yttrium (1 ppm) was used as an internal control for
normalization. All results were expressed as percent of injected dose.
Tissue transmission electron microscope (TEM)
The sections (100 nm) were imaged in a JEOL 1200 transmission electron microscope at 60
kV with digital images collected using a 1 k × 1 k Gatan BioScan camera Model 792.
Sample size justification and statistical analysis
We planed for n = 10 mice per treatment depending on the type of experiment. For an effect
size (ratio of fixed effect and residual SD) of 0.65, this sample size was sufficient to provide
80% power for a test at significance level of 0.05. As part of preliminary analysis, we
validated the normality assumption and proceeded with a nonparametric test as appropriate.
The Mann-Whitney test was performed to compare the tumor sizes and tumor nodule
number among different treatment groups.
In vivo safety study (blood chemistry and cytokine)
Plasma samples were collected from retro-orbital sinus and further analyzed for blood
chemistry [lactate dehydrogenase (LDH), blood urea nitrogen (BUN), and creatinine] and
proinflammatory cytokine production. Equivalent amounts of silicic acid (degradation
product of silicon particles) and saline were used as negative controls. Cytokine levels in the
supernatants were determined by ELISA kits according to the manufacturer's instructions
(Bio-Rad).
Results
Assembly of multistage system loaded with neutral nanoliposomal siRNA (DOPC-siRNA)
We fabricated S1MP using electrochemical etching and photolithography as previously
described (15). These methods allow for control over the size, shape, surface properties,
overall porosity, and pore size of the S1MP. For this study, we used half-dome shaped
S1MPs that were uniform in size with diameter of 1.6 ± 0.1 µm (Fig. 1A and C) and had
straight pores in the center with average pore size of 26 nm (Fig. 1D). The size and shape for
the S1MP were selected in accordance with the mathematical vector design criteria (18, 19).
In particular, the S1MP design was chosen to enhance the probability of their margination
and endothelial adhesion in capillary circulation. The S1MP were functionalized with an
amine group to provide for a positive surface charge (8.0 mV) to enhance the charge-based
interaction of negatively charged DOPC-siRNA (−2.9 mV) within the pores of the S1MP
(Supplementary Fig. S1). We first examined the loading capacity of the S1MP to achieve the
maximum loading of siRNA-DOPC. DOPC nanoliposomes containing Alexa555-labeled
siRNA (Alexa555-siRNA-DOPC) were used for direct measurement of loading. Alexa555-
siRNA-DOPC was efficiently incorporated into the S1MP in a concentration-dependent
manner (Fig. 1E). Gel electrophoresis also supported siRNA-DOPC dose-dependent loading
as well as the integrity of loaded siRNA (Fig. 1E). Under this loading condition, a maximum
2.0 pg of siRNA were loaded into a single S1MP (Fig. 1E). Effective loading of alexa555-
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siRNA-DOPC was achievable when dried and positively charged S1MP was used
(Supplementary Fig. S1), suggesting that the liposomes are loaded into the porous structure
by capillary action. Approximately 35% of Alexa555-siRNA-DOPC were released from the
S1MP within the first 3 hours (presumably associated with release from the surface and
shallow pores), followed by gradual release of the remaining amount from the S1MP over
14 days (Fig. 1F).
Effect of multistage delivery on siRNA tumor uptake and tissue distribution
To determine the duration and extent of siRNA-DOPC delivery in vivo, we first compared
siRNA distribution and tumor uptake using the S1MP loaded with Alexas555-siRNA-DOPC
versus Alexas555-siRNA-DOPC alone. Mice with HeyA8 orthotopic tumors (15 days after
i.p. inoculation of tumor cells) were given an i.v. injection of either S1MP loaded with a
single dose of Alexa555-siRNA-DOPC (5 µg siRNA) or a single dose of Alexa555-siRNA-
DOPC alone (5 µg siRNA). At day 10, siRNA fluorescence was almost absent in the tumors
from mice treated with Alexa555-siRNA-DOPC, whereas fluorescence remained for >10
days in the tumor from mice injected with S1MP-Alexa555-siRNA-DOPC (Supplementary
Fig. S2A). Overall, a single injection of the S1MP loaded with siRNA-DOPC resulted in
enhanced siRNA uptake into the tumor parenchyma by 6-fold compared with siRNA-DOPC
alone. No significant difference in Alexa555-siRNA uptake into other organs such as kidney
or liver was noted (Supplementary Fig. S2B and C).
In vivo delivery of siRNA-DOPC using the multistage system
Based on the sustained delivery observed in the experiments noted above, we next
investigated the duration and extent of gene silencing. We focused on EphA2 (receptor
tyrosine kinase in the ephrin family; ref. 20) because EphA2 is overexpressed in >70% of
ovarian cancers and is associated with poor patient outcome (21). We first evaluated the
immunostimulatory potential of EphA2 siRNA and/or the DOPC nanoliposomes because
immunologic effects, especially with certain sequences and delivery vehicles, have been
reported (22, 23). There were no biologically meaningful alterations noted in the cytokines
tested (Supplementary Fig. S3; ref. 24). We then optimized the siRNA dose required for
sustained gene silencing. Mice bearing SKOV3ip1 ovarian tumors were given an i.v.
injection of S1MP loaded with either single-dose EphA2-siRNA-DOPC (5 µg EphA2-
siRNA) or triple-dose EphA2-siRNA-DOPC (15 µg EphA2-siRNA). The mice were
sacrificed (three mice per time point) and the tumors were harvested at indicated time points
and assessed for EphA2 protein expression level (Fig. 2). A single administration of triple-
dose S1MP-EphA2-siRNA-DOPC resulted in >80% reduction of EphA2 expression and this
effect lasted for 3 weeks (Fig. 2A and B), whereas typically a single injection of EphA2-
siRNA-DOPC alone silenced EphA2 expression for only up to 5 to 6 days (13). S1MP
loaded with a single dose of EphA2-siRNA-DOPC failed to silence EphA2 gene expression
(data not shown). Sustained gene silencing in the tumor was also supported by
immunohistochemical analysis, which showed EphA2 downregulation for 28 days (Fig. 2C).
This sustained in vivo gene silencing in the tumor for at least 3 to 4 weeks following a single
injection is a major technical advance over frequent repetitive dosing.
Therapeutic effect of the multistage delivery of EphA2-siRNA-DOPC
Because multistage delivery of siRNA-DOPC resulted in sustained gene silencing, we next
tested the antitumor activity of this delivery method. Mice were treated either twice weekly
with siRNA-DOPC (5 µg EphA2-siRNA per injection, for a total administered dose of 30
µg EphA2-siRNA over 3 weeks) or a single administration with S1MP-EphA2-siRNA-
DOPC (15 µg EphA2-siRNA). No abnormal behavior or weight loss was noted during the
entire treatment period (Supplementary Fig. S4). Treatment with S1MP-EphA2-siRNA-
DOPC in mice with SKOV3ip1 tumor significantly reduced tumor weight by 54.2% and
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65.3% compared with nonsilencing control siRNA-DOPC and S1MP- nonsilencing control-
siRNA-DOPC, respectively (P < 0.05; ANOVA F = 4.92). Similarly, significant tumor
weight reduction was observed in the HeyA8 model treated with S1MP-EphA2-siRNA-
DOPC compared with nonsilencing control DOPC (57.4%) and S1MP-nonsilencing control-
siRNA-DOPC (69.3%), respectively (P < 0.01; ANOVA F = 5.89; Fig. 3A and B). These
data show that a single administration of S1MP-EphA2-siRNA-DOPC led to a comparable
antitumor effect to six repeated i.v. injections of EphA2-siRNA-DOPC for a total of twice
the siRNA dosage administered by the multistage strategy. The number of nodules formed
was also comparably reduced by both S1MP-EphA2-siRNA-DOPC and EphA2-siRNA-
DOPC in the SKOV3ip1 model (Supplementary Fig. S5). Tumor-bearing mice treated with
either S1MP-EphA2-siRNA-DOPC or EphA2-siRNA-DOPC alone did not develop ascites,
in contrast with control mice treated with either saline, S1MP alone, nonsilencing-siRNA-
DOPC, or S1MP-nonsilencing-siRNA-DOPC (Supplementary Fig. S6). We assessed the
biological effect of sustained downregulation of EphA2 by determining microvessel density
(CD31) and cell proliferation (Ki67). Representative sections from each treatment group are
shown with mean number of vessels per field or mean percent of proliferative cells.
Compared with control groups, the mean microvessel density was significantly reduced by
~3-fold in tumors treated with both S1MP-EphA2-siRNA-DOPC and EphA2-siRNA-DOPC
(overall ANOVA: **, P < 0.001; Fig. 4). Similarly, proliferation index was also
significantly reduced by 20-fold when mice were treated with both S1MP-EphA2- siRNA-
DOPC and EphA2-siRNA-DOPC (overall ANOVA: **, P < 0.001; Fig. 4).
Biodistribution and biodegradation of S1MP
To examine the biodistribution of S1MP, the mice were injected with Alexa555-siRNA-
DOPC loaded S1MP i.v. and the major organs including liver, kidney, spleen, lung, and
heart were harvested 4 hours after the injection. Silicon content analysis showed that S1MP
were primarily accumulated in the liver (53%) and spleen (11% of total injected dose), and
there was no to minimal S1MP accumulation observed in the kidney, lung, and heart (Fig.
5A). To provide further evidence that the S1MP allows sustained siRNA release, S1MP
conjugated with FITC (green fluorescence) were loaded with Alexa555-siRNA-DOPC (red
fluorescence) and i.v. injected into mice. The liver and spleen were harvested 20 days after
injection for histologic evaluation. Alexa555-siRNA-DOPC remained associated with S1MP
as evidenced by the yield of yellow fluorescence, but not with macrophages (pink) in the
liver and spleen at 20 days after injection (Supplementary Fig. S7A and B), indicating that
Alexa555-siRNA-DOPC remains intact. The S1MP were distributed throughout the liver
sinusoids and the red pulp in the spleen (Fig. 5B). Histopathologic analyses of tissue
sections with H&E stain showed no obvious inflammatory infiltration in these organs. In the
liver, the S1MPs were distributed throughout the sinusoids and (Fig. 5B) some were taken
up by Kupffer cells (Supplementary Fig. S7A). In the spleen, the S1MPs were present in the
splenic cords (Fig. 5B) and some were taken up by f4/80-positive macrophages
(Supplementary Fig. S7B). Transmission electron microscopic analyses of the liver and
spleen sections confirmed that S1MP remained within sinusoidal spaces in the liver and red
pulp in the spleen (Fig. 5C). Silicon contents in the spleen were reduced by 80% in the first
2 weeks and cleared by the 3rd week (Fig. 6A). In contrast, only 55% of S1MP was cleared
from the liver in the first 2 weeks and ~25% of the injected S1MP remained in the liver 3
weeks after injection (Fig. 6B), suggesting that S1MP degradation kinetics are different in
each organ. Scanning electron microscopic images of S1MP showed enlargement of pore
size at day 7 and reduction of overall size by day 14 (Fig. 6C). In some cases, bulky surface
erosion was noted (data not shown). Collectively, these data suggest that the S1MP serve as
a reservoir to protect siRNA-DOPC from degradation, release them over time by a
mechanism that combines degradation of the carrier material, and hindered diffusion
through the nanoscopic pore.
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Biocompatibility of S1MP
We next tested the biocompatibility of multistage delivery system in both an acute and
chronic setting in FBV/N mice following the i.v. administration of therapeutic dose of
S1MP-EphA2-siRNA-DOPC (15 µg EphA2-siRNA). Blood chemistry showed that S1MPs
did not cause a significant increase in any of the parameters tested (Supplementary Fig.
S8A–F). Despite significant accumulation of the S1MP in the liver and spleen, plasma LDH
levels from the liver and spleen remained unchanged (Supplementary Fig. S8A and D).
Similarly, tissue LDH levels in the liver and spleen were not changed at both conditions
tested (data not shown), indicating that accumulation of the S1MP in the liver and spleen did
not cause tissue injury. Similar to blood chemistry, the values of cytokines tested were not
significantly higher in the mice injected with DOPC-loaded S1MP than in the saline-injected
control animals in both acute and chronic setting, although some S1MP were taken up by
macrophages (Supplementary Fig. S8G and H). These data indicate that S1MP-siRNA-
DOPC is not toxic to the kidney, liver, and spleen and that no significant levels of
inflammatory cytokines were induced by the S1MP or its degradation products.
Discussion
The key findings from this work are that a single injection of multistage delivery system
comprised mesoporous silicon particles loaded with liposomal siRNA against oncogene,
EphA2, resulted in a sustained gene silencing for up to at least 3 weeks in ovarian tumor,
concomitant with a substantial reduction of tumor burden with no to minimum toxicity.
Many oncoproteins as well as their distinct roles have been identified in the past few
decades; however, many of them are “undrugable” with traditional approaches such as
small-molecule inhibitors because their crystal structures are unknown. We targeted
oncoprotein EphA2 (tyrosine kinase receptor in the ephrin family), which plays roles in
angiogenesis (25) and cell proliferation (26), and is difficult to target with conventional
approaches. EphA2 is absent in the normal tissue but is overexpressed in different types of
tumor including ovarian (27), breast (28), lung (29), and melanoma (30), with strong
association with poor survival, advanced-stage, or high-metastatic potential (31). Although
the dual roles of EphA2 as a pro-oncogenic or antioncogenic protein have been suggested
(32), a recent study revealed that EphA2 mediates cell migration and invasion in the absence
of ephrin (a cognate ligand for EphA2) through Akt phosphorylation (33). It has also been
reported that EphA2 overexpression is frequently accompanied by the loss of ephrin, further
supporting the pro-oncogenic role of EphA2 in cancer (34). Therefore, a disruption of the
biological functions of EphA2 is a highly attractive molecular-targeted therapy approach
(35).
Our data shown that the multistage delivery of liposomal siRNA (single injection of 15 µg
EphA2-siRNA) led to comparable antitumor effect to repeated i.v. siRNA-DOPC injections
(six injections of 5 µg EphA2-siRNA each), thus halving the siRNA dosage required to
achieve an equivalent antitumor effect. Although we are focusing on EphA2 in this study,
this platform could allow for highly adjustable personalized molecular targeted therapies
with a suitable combination of RNAi depending on the molecular signature of each tumor
type with “tunable” release kinetics of siRNA to control cancer cell growth. Many efforts
have been reported to deliver RNAi; viral vectors (36), chemically modified siRNA (6), and
nonviral nanocarriers including cationic liposome (37) and polycation-based carriers (38)
have shown effective gene silencing effects in vitro and in vivo. However, immunogenicity,
toxicity, safety concern, and unfavorable pharmacokinetics remain generally unsolved
problems for these delivery strategies. Traditional approaches to the improvement of
pharmacokinetics include surface functionalization of nanocarrier with polyethylene glycol
(PEG) to avoid reticuloendothelial system uptake (39). PEG, however, does not prevent
renal excretion and degradation of nanocarriers. In addition, PEGylation accelerates the
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clearance of nanocarrier from the circulation when injected repeatedly (40). Thus, with the
aim of providing stability to nanocarriers containing biologically active payload and of
achieving sustainedgene silencing, in this study, we used mesoporous silicon particles
(S1MP) as a carrier of DOPC neutral nanoliposomes. The serum half-life (t1/2) of
systemically injected DOPC nanoliposomes is ~2.7 hours.12 The combinatorial multistage
delivery system we used in this study significantly improved the pharmacokinetics of the
DOPC liposome and resulted in 3-week-long sustained gene silencing of EphA2 in the
tumor. It is likely that S1MP protect DOPC- siRNA from degradation and renal excretion
due to their entrapment within the capillary spaces within the liver and spleen (Fig. 5). Slow
release is most likely attained due to the gradual degradation of S1MP with subsequent
release of siRNA-DOPC that reaches to the tumor.
Porous silicon is an attractive material (41), which has been investigated for possible
applications in drug delivery by loading of nanoscale payload such as protein (42), enzymes
(43), drugs (41), and nanocarriers (15). The surface chemistry on the porous silicon will play
a critical role in determining the loading efficacy and release kinetics based on the type of
interaction of payload and porous surface (41). We used positively charged S1MP for
enhanced entrapment of the negatively charged (−2.9 mV) DOPC-siRNA. The electrostatic
interactions between the pore wall surface and liposomes are likely to contribute to the
sustained release of the liposomes from the porous structure as the S1MP degrades.
Mesoporous silicon is biocompatible (44, 45) and has received Food and Drug
Administration approval for use in brachytherapy and drug delivery from implants
(BioSilicon; ref. 46). The two delivery carrier materials used in this study, mesoporous
silicon and DOPC neutral liposome, are highly biodegradable, biocompatible, and combine
suitably to yield time-sustained delivery with no liver and renal toxicity in both in the acute
and the chronic setting, at a dose of 25 µg of mesoporous silicon (Supplementary Fig. S8).
In a separate study, we showed the safe systemic administration of 250 µg of mesoporous
(10-fold the dose used here) through both i.p. and i.v. routes in mice.13 The multistage
delivery system used in this study did not result in the production of the proinflammatory
cytokines tested, unlike other delivery system that relies on the host immunity (47). Our data
indicate that the antitumor effect mediated by the S1MP loaded with DOPC-siRNA was due
to the DOPC-siRNA-EphA2 mediated gene silencing of EphA2 and not due to
immunostimulatory effects.
Porous silicon is known to degrade completely into orthosilicic acid over time, which is
readily excreted from the body. The mechanism of sustained liposomal siRNA delivery is
likely to rely on essentially two unique characteristics and tailorable characteristics of the
S1MP: biodegradation and biodistribution. Biodegradation is controlled by the overall
porosity and pore size of the particles (48), which in turn is exquisitely controllable by
choice of material processing parameters (41). The biodistribution of the particles is
controlled by their size, shape, surface, and bulk properties (49), which are also precisely
controlled during the particle fabrication processes (15). In view of the different degradation
kinetics in different organs, and in particular within the liver and the spleen, altering their
respective accumulations will lead to different, adjustable kinetics of release of the
nanoliposome-encapsulated siRNA. Possible mechanisms involved in the geometry-
dependent organ sequestration of particles are capillary size, capillary architecture,
hemodynamics, and endocytosis (49).
12R.A. Nieves, T. Tanaka, C. Rodriguez-Aguayo, T. Madden, A.M. Tari, A.K. Sood, M. Ferrari, G. Lopez-Berestein, unpublished
data.
13T. Tanaka, B. Godin, R. Bhavane, R.A. Nieves, J. Gu, X. Liu, C. Chiappini, J.R. Fakhoury, S. Amra, A. Ewing, Q. Li, M. Ferrari,
unpublished data.
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In conclusion, in this study, we showed that a single injection of multistage delivery system
comprised of mesoporous silicon particles loaded with nanoliposomal siRNA against
oncogene, EphA2, resulted in: (a) sustained gene silencing for up to at least 3 weeks in
ovarian tumor; (b) substantial reduction of tumor burden; (c) substantial decrease of
angiogenesis and cellular proliferation; (d) no production of ascites; and (e) no detected
toxicity associated with the S1MP vectors, the neutral nanoliposomes, or the therapeutic
siRNA. To the best of our knowledge, this is the first study to achieve these collective goals
in vivo and, in particular, in two orthotopic models of ovarian cancer. These finding
encourage the development of a “library” of targets and drugs that can be further tailored
toward specific genetic abnormalities in cancer.
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Figure 1.
Assembly of S1MP-siRNA-DOPC. A, concept of multistage delivery system. B to D,
Scanning electron microscopic images of S1MP at different magnifications. E, loading of
Alexa555-siRNA-DOPC to the S1MP. After the loading, fluorescence from unincorporated
Alexa555-siRNA-DOPC was measured to assess the loading efficacy. S1MP loaded with
Alexa555-siRNA-DOPC were dissolved in 0.25% tetramethylammonium hydroxide and the
loaded siRNA were separated by gel electrophoresis and visualized with SYBR Gold. F,
release kinetics of Alexa555-siRNA-DOPC from the S1MP. The Alexa555-siRNA-DOPC–
loaded S1MP were incubated in 10% FBS and the supernatant was separated to measure
fluorescent intensity at Ex544/Em590 at different time points.
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Figure 2.
Systemic delivery of siRNA-DOPC using S1MP results in long-lasting in vivo gene
silencing. The mice (three mice per time point) bearing SKOV3ip1 orthotopic ovarian
tumors were injected with S1MP-EphA2-siRNA-DOPC or left nontreated. A, the tumors
were harvested at the indicated time points for Western blot to measure EphA2 expression
levels. Thirty micrograms of tumor lysate were separated on a 10% SDS-PAGE and
transferred on to a polyvinylidene difluoride membrane. The membrane was incubated with
anti-EphA2 antibody overnight at 4°C. The membrane was tested for β-actin to confirm
equal loading. B, densitometric analysis was performed to normalize EphA2 expression by
β-actin. Data were expressed as % of normalized value to the nontreated. C,
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immunohistochemical analysis of EphA2 expression in the SKOV1ip3 tumor. Images were
taken at original magnification of ×400.
Tanaka et al. Page 14
Cancer Res. Author manuscript; available in PMC 2011 October 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Therapeutic efficacy of sustained EphA2-siRNA-DOPC delivery by S1MP. Nude mice were
injected i.p. with SKOV3ip1 or HeyA8 cells and randomly allocated to one of six treatment
groups (n = 10): (a) saline, (b) S1MP, (c) nonsilencing control siRNA-DOPC, (d) S1MP-
nonsilencing control-siRNA-DOPC, (e) EphA2-siRNA-DOPC, (f) S1MP-EphA2-siRNA-
DOPC. SiRNA-DOPC was i.v. injected biweekly at a dose of 5 µg siRNA. S1MP-EphA2-
siRNA-DOPC was injected in a single administration in 3 wks at a dose of 15 µg siRNA.
The mice were injected with saline biweekly in the rest of treatment period. When control
animals (saline- and nonsilencing siRNA–treated mice) began to appear moribund (4–5 wks
after cell injection), all animals in an experiment were sacrificed and mouse weight, tumor
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weight (wt), tumor number, ascites volume, and tumor location were recorded. Columns,
mean tumor weight from SKOV3ip1 (A) or HeyA8 cells (B); bars, SD.
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Figure 4.
Effect of sustained siRNA delivery on angiogenesis and cell proliferation. Tumors from
animals with the SKOV3ip1 ovarian tumor were examined for microvessel density (CD31)
and cell proliferation (Ki67). Representative sections from each treatment group are shown
(final magnification, ×100 for CD31 and ×400 for Ki67), with mean number of vessels per
field or mean % of proliferative cells, summarized in the graph at the bottom. Five different
fields per slides, at least three individual tumors per treatment group were examined. Both
microvessel density (MVD; A and C) and cell proliferation (B and D) were significantly
reduced in tumor when treated with repeated administration of EphA2-siRNA-DOPC and a
single administration of the S1MP-EphA2-siRNA-DOPC. (overall ANOVA: **, P < 0.001).
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Figure 5.
Biodistribution of S1MP. A, silicon content analysis of organs isolated from mice (n = 6)
following i.v. injection of S1MP-EphA2-siRNA-DOPC. The major organs including heart,
lung, liver, kidney, and spleen were harvested 4 h after the i.v. injection. Silicon amounts
were measured by inductively coupled plasma atomic emission spectroscopy and expressed
as % of injected dose per organ (% ID). n.d., not detectable. B, H&E staining of the liver
and spleen sections. The liver and spleen were harvested from the mice injected with S1MP-
EphA2-siRNA-DOPC and fixed with formalin. Five-micrometer paraffin sections were
stained with H&E to identify the localization of S1MP in the organs. Arrows, S1MP (final
magnification, ×1,000). C, transmission electron microscopic images of S1MP in the liver
and spleen. S1MP remained within the sinusoidal space in the liver (red arrow). K, Kupffer
cell; R, RBC; SS, sinusoidal space; H, hepatocyte; M, macrophage (original magnification,
×10,000).
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Figure 6.
Biodegradation of S1MP. The mice (n = 5) were injected with S1MP-Alexa555-siRNA-
DOPC and the liver and spleen were harvested at indicated time points. The organs were
processed for silicon contents analysis and SEM images. A and B, inductively coupled
plasma analysis was performed to determine the silicon contents in the liver and spleen at
different time points. Silicon (Si) amounts were expressed as % of injected dose per organs
(% ID). C, the S1MPs were isolated from the liver and spleen homogenates and further
cleaned by sonication for SEM analysis. SEM images show time-dependent biodegradation
of S1MP in the liver and spleen at day 7 and 15. Original magnification, ×50,000).
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